RESUMEN
BACKGROUND: Osteosarcomas are the most common primary malignant tumors of bone, showing complex chromosomal rearrangements with multiple gains and losses. A frequent deletion within the chromosomal region 3q13.31 has been identified by us and others, and is mainly reported to be present in osteosarcomas. The purpose of the study was to further characterize the frequency and the extent of the deletion in an extended panel of osteosarcoma samples, and the expression level of the affected genes within the region. We have identified LSAMP as the target gene for the deletion, and have studied the functional implications of LSAMP-reexpression. METHODS: LSAMP copy number, expression level and protein level were investigated by quantitative PCR and western blotting in an osteosarcoma panel. The expression of LSAMP was restored in an osteosarcoma cell line, and differences in proliferation rate, tumor formation, gene expression, migration rate, differentiation capabilities, cell cycle distribution and apoptosis were investigated by metabolic dyes, tumor formation in vivo, gene expression profiling, time-lapse photography, differentiation techniques and flow cytometry, respectively. RESULTS: We found reduced copy number of LSAMP in 45/76 osteosarcoma samples, reduced expression level in 25/42 samples and protein expression in 9/42 samples. By restoring the expression of LSAMP in a cell line with a homozygous deletion of the gene, the proliferation rate in vitro was significantly reduced and tumor growth in vivo was significantly delayed. In response to reexpression of LSAMP, mRNA expression profiling revealed consistent upregulation of the genes hairy and enhancer of split 1 (HES1), cancer/testis antigen 2 (CTAG2) and kruppel-like factor 10 (KLF10). CONCLUSIONS: The high frequency and the specificity of the deletion indicate that it is important for the development of osteosarcomas. The deletion targets the tumor suppressor LSAMP, and based on the functional evidence, the tumor suppressor function of LSAMP is most likely exerted by reducing the proliferation rate of the tumor cells, possibly by indirectly upregulating one or more of the genes HES1, CTAG2 or KLF10. To our knowledge, this study describes novel functions of LSAMP, a first step to understanding the functional role of this specific deletion in osteosarcomas.
Asunto(s)
Antígenos de Neoplasias/genética , Antígenos de Superficie/genética , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Neoplasias Óseas/genética , Moléculas de Adhesión Celular Neuronal/genética , Factores de Transcripción de la Respuesta de Crecimiento Precoz/genética , Regulación Neoplásica de la Expresión Génica , Proteínas de Homeodominio/genética , Factores de Transcripción de Tipo Kruppel/genética , Osteosarcoma/genética , Antígenos de Neoplasias/metabolismo , Antígenos de Superficie/metabolismo , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Neoplasias Óseas/metabolismo , Neoplasias Óseas/mortalidad , Neoplasias Óseas/patología , Moléculas de Adhesión Celular Neuronal/metabolismo , Línea Celular Tumoral , Proliferación Celular/genética , Mapeo Cromosómico , Cromosomas Humanos Par 3 , Factores de Transcripción de la Respuesta de Crecimiento Precoz/metabolismo , Femenino , Proteínas Ligadas a GPI/genética , Proteínas Ligadas a GPI/metabolismo , Eliminación de Gen , Dosificación de Gen , Prueba de Complementación Genética , Proteínas de Homeodominio/metabolismo , Homocigoto , Humanos , Factores de Transcripción de Tipo Kruppel/metabolismo , Masculino , Tasa de Mutación , Osteosarcoma/metabolismo , Osteosarcoma/mortalidad , Osteosarcoma/patología , ARN Mensajero/genética , ARN Mensajero/metabolismo , Transducción de Señal , Análisis de Supervivencia , Factor de Transcripción HES-1RESUMEN
Wnt/ß-catenin is a major regulator of stem cell self-renewal and differentiation and this signaling pathway is aberrantly activated in a several cancers, including osteosarcoma (OS). Attenuation of Wnt/ß-catenin activity by tankyrase inhibitors is an appealing strategy in treatment of OS. The efficacy of the tankyrase inhibitor JW74 was evaluated in three OS cell lines (KPD, U2OS, and SaOS-2) both at the molecular and functional level. At the molecular level, JW74 induces stabilization of AXIN2, a key component of the ß-catenin destruction complex, resulting in reduced levels of nuclear ß-catenin. At the functional level, JW74 induces reduced cell growth in all three tested cell lines, in part due to a delay in cell cycle progression and in part due to an induction of caspase-3-mediated apoptosis. Furthermore, JW74 induces differentiation in U2OS cells, which under standard conditions are resistant to osteogenic differentiation. JW74 also enhances differentiation of OS cell lines, which do not harbor a differentiation block. Interestingly, microRNAs (miRNAs) of the let-7 family, which are known tumor suppressors and inducers of differentiation, are significantly upregulated following treatment with JW74. We demonstrate for the first time that tankyrase inhibition triggers reduced cell growth and differentiation of OS cells. This may in part be due to an induction of let-7 miRNA. The presented data open for novel therapeutic strategies in the treatment of malignant OS.
Asunto(s)
Neoplasias Óseas/tratamiento farmacológico , Diferenciación Celular/efectos de los fármacos , Osteosarcoma/tratamiento farmacológico , Oxadiazoles/administración & dosificación , Tanquirasas/genética , Triazoles/administración & dosificación , Antineoplásicos/administración & dosificación , Apoptosis/efectos de los fármacos , Complejo de Señalización de la Axina/genética , Neoplasias Óseas/patología , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Humanos , Osteogénesis/genética , Osteosarcoma/genética , Osteosarcoma/patología , Tanquirasas/antagonistas & inhibidores , Vía de Señalización Wnt/genéticaRESUMEN
BACKGROUND: The normal stem cell marker CD133 is also a putative marker of cancer stem cells (CSCs) in different types of cancers. Hence, a major challenge when targeting CD133-expressing CSCs is to prevent depletion of the normal stem cell pool. We hypothesized that the site-specific and light-controlled drug delivery method photochemical internalization (PCI) may have the potential to enhance selectivity and endosomal escape of CD133-targeting immunotoxins in stem-like sarcoma cells. METHODS: We have used a sarcoma model, SW872 cells isolated from xenografts harboring CSCs within a ~2% CD133(high) subpopulation to investigate the potential of PCI of CD133-targeting toxin as a novel strategy to kill CSCs. Model immunotoxins were generated by binding the ribosome-inactivating protein toxin saporin to each of the monoclonal antibodies CD133/1 (AC133) or CD133/2 (293C), specific for individual CD133-epitopes. Cellular targeting, intracellular co-localization with the PCI photosensitizer, disulfonated meso-tetraphenylchlorin (TPCS2a), and cytotoxic efficacy of PCI of the CD133-targeting toxins were evaluated. RESULTS: PCI of CD133-saporin efficiently targets CD133-expressing SW872 and HT1080 sarcoma cells and results in loss of cell viability. Following sub-toxic treatment, surviving SW872 cells, depleted of the CD133-expressing population, display reduced proliferative capacity and attenuated CSC properties, such as reduced colony-forming ability and tumorigenicity. CONCLUSION: Here we present a proof-of-concept study, where PCI enables light-triggered delivery of CD133-targeting antibody-drug conjugates, resulting in decreased sarcoma tumor-initiating capacity. GENERAL SIGNIFICANCE: PCI of CD133-targeting toxins may be used as a minimal invasive strategy in the treatment of sarcomas, and potentially as a therapeutic for other solid tumors expressing CD133.
Asunto(s)
Glicoproteínas/antagonistas & inhibidores , Inmunotoxinas/administración & dosificación , Células Madre Neoplásicas/efectos de los fármacos , Péptidos/antagonistas & inhibidores , Fármacos Fotosensibilizantes/administración & dosificación , Sarcoma/tratamiento farmacológico , Antígeno AC133 , Animales , Antígenos CD/inmunología , Línea Celular Tumoral , Sistemas de Liberación de Medicamentos , Glicoproteínas/inmunología , Humanos , Ratones , Ratones SCID , Péptidos/inmunología , Fotoquímica , Sarcoma/patología , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
BACKGROUND: Relatively few sarcomas harbor TP53 (tumor protein p53) mutations, but in many cases, amplification of MDM2 (murine double minute 2) effectively inactivate p53. The p53 pathway activity can also be affected by normal genetic variation. METHODS: The mutation status of TP53 and expression of MDM2, TP53, and their genetic variants SNP309 and R72P (Arg72Pro) were investigated in 125 sarcoma patient samples and 18 sarcoma cell lines. Association of the different genotypes and gene aberrations with chemotherapy response and survival, as well as response to MDM2 antagonists in vitro was evaluated. RESULTS: Twenty-two percent of the tumors had mutant TP53 and 20% MDM2 gene amplification. Patients with wild-type TP53 (TP53(Wt) ) tumors had improved survival (P < .001) and TP53(Wt) was an independent prognostic factor (hazard ratio = 0.41; 95% confidence interval = 0.23-0.74; P = .03). Interestingly, there was a trend toward longer time to progression after chemotherapy for tumors with the apoptosis-prone p53 variant R72 (P = .07), which was strongest with doxorubicin/ifosfamide-based regimens (P = .01). Liposarcomas had low R72 frequency (33% versus 56%), but increased levels of MDM2 and MDM4 (51% and 11%, P < .001). MDM2 overexpression on a TP53(Wt) background predicted better response to MDM2 antagonist Nutlin-3a, irrespective of R72P or SNP309 status. CONCLUSIONS: Improved survival after chemotherapy was found in patients with TP53(Wt) tumors harboring the R72 variant. MDM2 overexpression in TP53(Wt) tumors predicted good response to MDM2 antagonists, irrespective of R72P or SNP309 status. Thus, detailed TP53 and MDM2 genotype analyses prior to systemic therapy are recommended.
Asunto(s)
Genes p53 , Proteínas Proto-Oncogénicas c-mdm2/genética , Sarcoma/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Línea Celular Tumoral , Niño , Femenino , Genotipo , Humanos , Imidazoles/uso terapéutico , Masculino , Persona de Mediana Edad , Mutación , Piperazinas/uso terapéutico , Polimorfismo de Nucleótido Simple , Proteínas Proto-Oncogénicas c-mdm2/antagonistas & inhibidores , Sarcoma/tratamiento farmacológico , Sarcoma/mortalidad , Resultado del Tratamiento , Adulto JovenRESUMEN
Liposarcoma cell lines represent in vitro models for studying disease mechanisms at the cellular level and for preclinical evaluation of novel drugs. To date there are a limited number of well-characterized models available. In this study, nine immortal liposarcoma cell lines were evaluated for tumor-forming ability, stem cell- and differentiation potential, and metastatic potential, with the aim to generate a well-characterized liposarcoma cell line panel. Detailed stem cell and differentiation marker analyses were also performed. Five of the liposarcoma cell lines were tumorigenic, forming tumors in mice. Interestingly, tumor-forming ability correlated with high proliferative capacity in vitro. All the cell lines underwent adipocytic differentiation, but the degree varied. Surprisingly, the expression of stem cell and differentiation markers did not correlate well with function. Overall, the panel contains cell lines suited for in vivo analyses (LPS141, SA-4, T778, SW872, and LISA-2), for testing novel drugs targeting cancer stem cells (LPS141) and for studying tumor progression and metastasis (T449 and T778).
RESUMEN
Aldehyde dehydrogenase (ALDH) has recently been shown to be a marker of cancer stem-like cells (CSCs) across tumour types. The primary goals of this study were to investigate whether ALDH is expressed in liposarcomas, and whether CSCs can be identified in the ALDHhigh subpopulation. We have demonstrated that ALDH is indeed expressed in 10 out of 10 liposarcoma patient samples. Using a liposarcoma xenograft model, we have identified a small population of cells with an inducible stem cell potential, expressing both ALDH and CD133 following culturing in stem cell medium. This potential CSC population, which makes up for 0,1-1,7 % of the cells, displayed increased self-renewing abilities and increased tumourigenicity, giving tumours in vivo from as few as 100 injected cells.
RESUMEN
Nonmammalian glycan structures from helminths act as Th2 adjuvants. Some of these structures are also common on plant glycoproteins. We hypothesized that glycan structures present on peanut glycoallergens act as Th2 adjuvants. Peanut Ag (PNAg), but not deglycosylated PNAg, activated monocyte-derived dendritic cells (MDDCs) as measured by MHC/costimulatory molecule up-regulation, and by their ability to drive T cell proliferation. Furthermore, PNAg-activated MDDCs induced 2- to 3-fold more IL-4- and IL-13-secreting Th2 cells than immature or TNF/IL-1-activated MDDCs when cultured with naive CD4+ T cells. Human MDDCs rapidly internalized Ag in a calcium- and glycan-dependent manner consistent with recognition by C-type lectin. Dendritic cell (DC)-specific ICAM-grabbing nonintegrin (DC-SIGN) (CD209) was shown to recognize PNAg by enhanced uptake in transfected cell lines. To identify the DC-SIGN ligand from unfractionated PNAg, we expressed the extracellular portion of DC-SIGN as an Fc-fusion protein and used it to immunoprecipitate PNAg. A single glycoprotein was pulled down in a calcium-dependent manner, and its identity as Ara h 1 was proven by immunolabeling and mass spectrometry. Purified Ara h 1 was found to be sufficient for the induction of MDDCs that prime Th2-skewed T cell responses. Both PNAg and purified Ara h 1 induced Erk 1/2 phosphorylation of MDDCs, consistent with previous reports on the effect of Th2 adjuvants on DCs.
Asunto(s)
Adyuvantes Inmunológicos/fisiología , Alérgenos/metabolismo , Arachis/inmunología , Moléculas de Adhesión Celular/metabolismo , Células Dendríticas/metabolismo , Glicoproteínas/metabolismo , Lectinas Tipo C/metabolismo , Proteínas de Plantas/metabolismo , Receptores de Superficie Celular/metabolismo , Células Th2/inmunología , Adyuvantes Inmunológicos/metabolismo , Alérgenos/inmunología , Antígenos de Plantas , Células Cultivadas , Técnicas de Cocultivo , Glicoproteínas/inmunología , Humanos , Ligandos , Proteínas de la Membrana , Proteínas de Plantas/inmunologíaRESUMEN
BACKGROUND: Two forms of IgE-mediated skin reactions, atopic dermatitis (AD) and urticaria, have been associated with milk allergy. The reason for these distinct reactions is poorly understood. T cells expressing cutaneous lymphocyte antigen (CLA), a unique skin-homing receptor, are known to play an important role in AD. In contrast, the role of lymphocytes in patients with milk-induced urticaria is unclear. OBJECTIVE: The expression of the skin-specific homing receptor CLA after in vitro milk protein-specific stimulation was investigated to determine whether T-lymphocyte homing to the skin plays a role in food-induced urticaria. METHODS: Fourteen patients with milk-induced urticaria but no evidence of AD were included in the study and compared with 6 children with milk-induced AD, 6 children with milk-induced gastrointestinal diseases, and 6 nonatopic and 6 atopic individuals without milk allergy. PBMCs were cultured in the presence or absence of caseins or tetanus toxoid. T-cell proliferation was determined, and T-cell phenotyping was performed by means of flow cytometry with anti-CD4, anti-CD8, and anti-CLA mAbs. RESULTS: After in vitro stimulation with caseins, PBMCs from patients with milk-induced urticaria and AD had a significantly greater percentage of CD4(+) T cells expressing CLA than patients with milk-induced gastrointestinal symptoms and atopic or nonatopic control subjects. After tetanus stimulation in vitro, no significant difference between the groups was observed. T cells from both patients with milk-induced urticaria and control subjects proliferated well in response to caseins and tetanus. CONCLUSION: Lymphocytes expressing CLA are selectively activated in patients with milk-induced urticaria and may play an important role in the pathogenesis of this disease. Expression of CLA is not unique to milk-induced inflammation in the skin of patients with AD and milk allergy.
Asunto(s)
Glicoproteínas de Membrana/análisis , Hipersensibilidad a la Leche/complicaciones , Linfocitos T/inmunología , Urticaria/etiología , Adolescente , Adulto , Antígenos de Diferenciación de Linfocitos T , Antígenos de Neoplasias , Caseínas/farmacología , Células Cultivadas , Niño , Preescolar , Dermatitis Atópica/etiología , Humanos , Inmunoglobulina E/sangre , Lactante , Activación de Linfocitos , Persona de Mediana Edad , Hipersensibilidad a la Leche/inmunología , Factor de Necrosis Tumoral alfa/biosíntesisRESUMEN
BACKGROUND: A number of gastrointestinal disorders, including allergic eosinophilic gastroenteritis and food protein-induced enteropathy, have been associated with milk hypersensitivity. The immunologic reactions appear to involve T cells that are activated by specific food proteins. OBJECTIVE: The present study was performed to examine the cytokine profiles of milk-specific lymphocytes from the duodenal lamina propria from children with milk-induced gastrointestinal diseases. METHODS: Duodenal biopsy specimens obtained from 10 patients with allergic eosinophilic gastroenteritis, food protein-induced enteropathy, or both and 12 control subjects were mechanically minced and cultured with either mitogens (i.e., polyclonal T-cell expansion) or milk proteins (i.e., milkspecific T-cell expansion). By using flow cytometry, expanded T cells were phenotyped with anti-CD4, anti-CD8, anti-IL-4, anti-IL-5, and anti-IFN-gamma mAbs. The milk specificity of the lines was evaluated by means of the lymphocyte proliferation assay. In addition, the release of T(H)1, T(H)2, and T(H)3 cytokines was determined after restimulation. RESULTS: In patients and control subjects polyclonal expansion of mucosal lymphocytes resulted in predominantly T(H)1 cells. Milk-specific mucosal T-cell lines could be established in 60% of the patients but in none of the control subjects. In contrast to the polyclonal expansion of T cells, the milk-specific expansion of mucosal T cells showed a clear T(H)2 cytokine profile. On restimulation with milk protein, these cells showed a high proliferative response. They released T(H)2 cytokines, predominately IL-13, but failed to release T(H)3 cytokines important in the development of oral tolerance. CONCLUSION: The release of T(H)2 cytokines after stimulation of milk-specific mucosal T cells may play a pathogenic role in the inflammatory changes seen in milk-induced gastrointestinal disorders.